DOCSLIB.ORG

The Word Pharmacy Is from the Greek 'The Poison of a Witch'

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Word Pharmacy Is from the Greek 'The Poison of a Witch' SINthetic Pharmaceutical = ‘Poison of the Witch’ The Word Pharmacy is from the Greek ‘The Poison of a Witch’ 1 SINthetic Pharmaceutical = ‘Poison of the Witch’ When a large percentage of the drugs once approved for sale need to be removed for hurting people, We must see that there is something extremely wrong with the Approval process. What is wrong is that SINthetic Patented PHARMACeuticals are trully the ‘Poison of the Witch’. 2 SINthetic Pharmaceutical = ‘Poison of the Witch’ This Book will list some of these removed drugs and explain the danger. 3 SINthetic Pharmaceutical = ‘Poison of the Witch’ 4 SINthetic Pharmaceutical = ‘Poison of the Witch’ 5 SINthetic Pharmaceutical = ‘Poison of the Witch’ 6 SINthetic Pharmaceutical = ‘Poison of the Witch’ 7 SINthetic Pharmaceutical = ‘Poison of the Witch’ 8 SINthetic Pharmaceutical = ‘Poison of the Witch’ 9 SINthetic Pharmaceutical = ‘Poison of the Witch’ 10 SINthetic Pharmaceutical = ‘Poison of the Witch’ 11 SINthetic Pharmaceutical = ‘Poison of the Witch’ 12 SINthetic Pharmaceutical = ‘Poison of the Witch’ 13 SINthetic Pharmaceutical = ‘Poison of the Witch’ 14 SINthetic Pharmaceutical = ‘Poison of the Witch’ 15 SINthetic Pharmaceutical = ‘Poison of the Witch’ 16 SINthetic Pharmaceutical = ‘Poison of the Witch’ 17 SINthetic Pharmaceutical = ‘Poison of the Witch’ This is a list of the Major drugs once approved for use now recalled a dangerous Australia, France, Oxyphenisatin (Phenisatin) Hepatotoxicity.[3] Germany, UK, US [3] Secobarbital France, Norway, others. Self poisoning. Marketed as a psychiatric 1950 drug; withdrawn after it Lysergic acid s– became widely used diethylamide (LSD) 1960 recreationally. Now illegal in s most of the world. [3][53] Thenalidine 1960 Canada, UK, US Neutropenia Withdrawn because of risk of teratogenicity;[52] returned to market for use Thalidomide 1961 Germany in leprosy and multiple myeloma under FDAorphan drug rules Cataracts, alopecia, Triparanol 1962 France, US ichthyosis.[3] [9] Bunamiodyl 1963 Canada, UK, US Nephropathy. Genotoxicity.[13] withdrawn Dantron 1963 Canada, UK, US from general use in UK but permitted in terminal patients 18 SINthetic Pharmaceutical = ‘Poison of the Witch’ [20] Ethyl carbamate 1963 Canada, UK, US, Carcinogenicity. [3] Benziodarone 1964 France, UK Jaundice. Butamben (Efocaine)(Butoform Dermatologic toxicity; 1964 US e) psychiatric Reactions.[3] Cardiovascular and Dithiazanine iodide 1964 France, US metabolic reaction.[3] [3] Iodinated casein strophantin 1964 US Metabolic reaction. Interactions with food Iproniazid 1964 Canada products containing tyrosine.[22] Unspecific experimental Metofoline 1965 US toxicity.[3] [3] Pronethalol 1965 UK Animal carcinogenicity. [3] Xenazoic acid 1965 France Hepatotoxicity. Hepatotoxicity, drug Phenoxypropazine 1966 UK intereaction.[3] [3] Bithionol 1967 US Dermatologic toxicity. 19 SINthetic Pharmaceutical = ‘Poison of the Witch’ [3] Ibufenac 1968 UK Hepatotoxicity, jaundice. [3] Anagestone acetate 1969 Germany Animal carcinogenicity. [3] Chlorphentermine 1969 Germany Cardiovascular Toxicity. [3] Cloforex 1969 Germany Cardiovascular toxicity. Dermatologic and ophthalmic Amoproxan 1970 France toxicity.[3] Chlormadinone(Chlormenadion 1970 UK, US Animal Carcinogenicity.[3] e) 1970 Risk of teratogenicity[citation Diethylstilbestrol needed] s [3] Dihydrostreptomycin 1970 US Neuropsychiatric reaction. Jaundice, elevated hepatic Fenclozic acid 1970 UK, US enzymes.[3] [3] Diacetoxydiphenolisatin 1971 Australia Hepatotoxicity. [3] Triacetyldiphenolisatin 1971 Australia Hepatotoxicity. Dimazole (Diamthazole) 1972 France, US Neuropsychiatric reaction.[3] 20 SINthetic Pharmaceutical = ‘Poison of the Witch’ France, Germany, UK, [3] Clioquinol 1973 Neurotoxicity. US Hepatotoxicity, drug Nialamide 1974 UK, US intereaction.[3] Agranulocytosis, Dipyrone(Metamizole) 1975 UK, US, Others anaphylactic reactions.[3] Hepatotoxicity, drug Mebanazine 1975 UK intereaction.[3] An ingredient in "A.P.C." tablet; withdrawn because of risk of cancer and kidney Phenacetin 1975 Canada disease[32] Germany Denmark, UK, US, others Reason: nephropathy.[3] [3] Azaribine 1976 US Thromboembolism. [29] Oxeladin 1976 Canada, UK, US (1976) Carcinogenicity. Pifoxime (=Pixifenide) 1976 France Neuropsychiatric reaction.[3] Phenformin and Buformin 1977 France, Germany US Severe lactic acidosis[3] [3] Buformin 1978 Germany Metabolic toxicity. 21 SINthetic Pharmaceutical = ‘Poison of the Witch’ [3] Alclofenac 1979 UK Vasculitis, Rash. [3] Methapyrilene 1979 Germany, UK, US Animal carcinogenicity. [3] Pyrovalerone 1979 France Abuse. [3] Amobarbital 1980 Norway Self poisoning. [3] Cyclobarbital 1980 Norway Self poisoning. [3] Pentobarbital 1980 Norway Self poisoning. Germany, France, UK, Ticrynafen(Tienilic acid) 1980 Liver toxicity and death.[3] US others 1981 Hemolytic Anemia, France, Germany, Spain, Nomifensine - hepatotoxicity, serious UK, US, others 1986 hypersensitive reactions.[2][3] Liver and kidney failure; Benoxaprofen 1982 Germany,Spain, UK, US gastrointestinal bleeding; ulcers.[2][3] [3] Clomacron 1982 UK Hepatotoxicity. France, Germany, UK, [3] Methandrostenolone 1982 Off-label abuse. US, others 22 SINthetic Pharmaceutical = ‘Poison of the Witch’ Withdrawn for inability to produce effective convulsive Pentylenetetrazol 1982 therapy, and for causing seizures. Voluntarily withdrawn from market by Lily.[15]:12Reintroduced as a dietary supplement in Dimethylamylamine (DMAA) 1983 US 2006;[15]:13 and in 2013 the FDA started work to ban it due to cardiovascular problems[16] Animal carcinogenicity, Indoprofen 1983 Germany, Spain, UK gastrointestinal toxicity.[3] France, Germany, Spain, [3] Isoxicam 1983 Stevens johnson syndrome. others [3] Propanidid 1983 UK Allergy. Risk of Guillain-Barré syndrome, hypersensitivity Zimelidine 1983 Worldwide reaction, hepatotoxicity[3][57][58] banned worldwide.[59] Anaphylactic reactions and Zomepirac 1983 UK, Germany, Spain, US non-fatal allergic reactions, renal failure[2][3] 23 SINthetic Pharmaceutical = ‘Poison of the Witch’ Althesin (=Alphaxoloneaminept 1984 France, Germany, UK Anaphylaxis.[3] ine + Alphadolone) Unspecific experimental Antrafenine 1984 France toxicity.[3] Cutaneous reactions; animal Fenclofenac 1984 UK carcinogenicity.[3] Cutaneous reaction, Feprazone 1984 Germany, UK multiorgan toxicity.[3] [3] Glafenine 1984 France, Germany Anaphylaxis. [3] Isaxonine phosphate 1984 France Hepatotoxicity. South Africa (1971), India Withdrawn because of risk [26][2 Methaqualone 1984 (1984), United Nations of addiction and overdose (1971-1988) 7] Hepatic and hematologic Nitrefazole 1984 Germany toxicity.[3] 1984 Bone marrow suppression, UK, US, Germany, Oxyphenbutazone - Steven Johnson France, Canada 1985 Syndrome.[3][30] France, Germany, Spain, [3] Cianidanol 1985 Hemolytic Anemia. Sweden 24 SINthetic Pharmaceutical = ‘Poison of the Witch’ [3] Indalpine 1985 France Agranulocytosis. Neurologic and hepatic Perhexilene 1985 UK, Spain toxicity.[3] Off-label abuse, hematologic Phenylbutazone 1985 Germany toxicity.[3] [3] Suloctidyl 1985 Germany, France, Spain Hepatotoxicity. Renal toxicity, animal Beta-ethoxy-lacetanilanide 1986 Germany carcinogenicity.[3] [3] Bucetin 1986 Germany Renal toxicity. [3] Canrenone 1986 Germany Animal Carcinogenicity. [3] Difemerine 1986 Germany Multi-Organ toxicities. Dermatologic and Sulfamethoxypyridazine 1986 UK hematologic reactions.[3] 1986 Flank pain, decreased kidney Suprofen - UK, Spain, US function.[2][3] 1987 [3] Clometacin 1987 France Hepatotoxicity. 25 SINthetic Pharmaceutical = ‘Poison of the Witch’ [3] Cyclofenil 1987 France Hepatotoxicity. France, [3] Muzolimine 1987 Germany,European Polyneuropathy. Union [3] Vincamine 1987 Germany Hematologic toxicity. [10][11] Cinepazide 1988 Spain Agranulocytosis. [3] Nikethamide 1988 multiple markets CNS Stimulation. Canada,France, Cardiac arrythmia[37] and Prenylamine 1988 Germany, UK, US, others death.[3] Dermatologic, hematologic Sulfacarbamide 1988 Germany and hepatic reactions .[3] [3] Sulfamethoxydiazine 1988 Germany Unknown. [3] Broazolam 1989 UK Animal carcinogenicity. Withdrawn US (1999). Risk Etretinate 1989 France for birth defects.[2][3] [3] Exifone 1989 France Hepatotoxicity. 26 SINthetic Pharmaceutical = ‘Poison of the Witch’ Eosinophilic myalgia [3] L-tryptophan 1989 Germany, UK syndrome. Still sold in the US [3] Proglumide 1989 Germany Respiratory reaction. [3] Dilevalol 1990 UK Hepatotoxicity. Uterine hypotonus, fetal Dinoprostone 1990 UK distress.[3] [3] Fenoterol 1990 New Zealand Asthma mortality. [3] Metipranolol 1990 UK, others Uveitis. [3][36]:223 Pirprofen 1990 France, Germany, Spain Liver toxicity. [2][3] Encainide 1991 UK, US Ventricular arrhythmias. [3] Fipexide 1991 France Hepatotoxicity. [3] Flunitrazepam 1991 France Abuse. Prolonged QT interval, Germany, UK, Spain, Terodiline (Micturin) 1991 ventricular tachycardia and others arrhythmia.[3] 27 SINthetic Pharmaceutical = ‘Poison of the Witch’ France, Netherlands, Psychiatric adverse drug Triazolam 1991 Finland, Argentina, UK reactions, amnesia.[3][56] others [3] Benzarone 1992 Germany Hepatitis. Low blood sugar; hemolytic anemia; kidney, liver Temafloxacin 1992 Germany, UK, US, others dysfunction; allergic reactions[2][3] Allergic reactions and cases Temafloxacin 1992 US of hemolytic anemia, leading to three patient deaths.[2] [3] Bendazac 1993 Spain Hepatotoxicity. Increased mortality at higher Flosequinan (Manoplax) 1993 UK, US doses; increased hospitalizations.[2][3] [3] Ketorolac 1993 France, Germany, others Hemorrhage, renal
Load more

Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • 1 441 702 B1
    (19) TZZ__Z _T (11) EP 1 441 702 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4045 (2006.01) A61P 25/20 (2006.01) 10.05.2017 Bulletin 2017/19 A61K 9/20 (2006.01) (21) Application number: 02760523.7 (86) International application number: PCT/IL2002/000662 (22) Date of filing: 12.08.2002 (87) International publication number: WO 2003/015690 (27.02.2003 Gazette 2003/09) (54) METHOD FOR TREATING PRIMARY INSOMNIA VERFAHREN ZUR BEHANDLUNG PRIMÄRER INSOMNIA METHODE DE TRAITEMENT DE L’INSOMNIE PRIMAIRE (84) Designated Contracting States: • ROTH T ET AL: "Consensus for the AT BE BG CH CY CZ DE DK EE ES FI FR GB GR pharmacological management of insomnia in th IE IT LI LU MC NL PT SE SK TR enew millennium", INTERNATIONAL JOURNAL Designated Extension States: OF CLINICAL PRACTICE, MEDICON LT LV RO SI INTERNATIONAL, ESHER, GB, vol. 55, no. 1, 1 January 2001 (2001-01-01), page 10PAGES, (30) Priority: 14.08.2001 IL 14490001 XP002990688, ISSN: 1368-5031 • PERLIS M L ET AL: "Psychophysiological (43) Date of publication of application: insomnia: the behavioural model and a 04.08.2004 Bulletin 2004/32 neurocognitive perspective", JOURNAL OF SLEEP RESEARCH, BLACKWELL SCIENTIFIC, (60) Divisional application: OXFORD, GB, vol. 6, 1 January 1997 (1997-01-01), 16172415.8 / 3 103 443 pages 179-188, XP002990686, ISSN: 0962-1105, DOI: DOI:10.1046/J.1365-2869.1997.00045.X (73) Proprietor: NEURIM PHARMACEUTICALS (1991) • SILVA J A C E ET AL: "Special report from a LIMITED symposium held by the WHO and the World Tel Aviv 69710 (IL) Federation of sleep research societies: an overview of insomnias and related disorders - (72) Inventor: ZISAPEL, Nava recognition, epidemiology and rational 69355 Tel Aviv (IL) management", SLEEP, ALLEN PRESS, LAWRENCE, KS,US, vol.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,365,521 B2 Blackburn Et Al
    USOO9365521B2 (12) United States Patent (10) Patent No.: US 9,365,521 B2 Blackburn et al. (45) Date of Patent: Jun. 14, 2016 (54) NON-HYGROSCOPICSALTS OF 5-HT, 5,178,786 A 1/1993 Jahnke et al. AGONSTS 5,247,080 A 9/1993 Berger et al. 5,275,915 A 1/1994 Kojima et al. 5,387,685 A 2f1995 Powell et al. (75) Inventors: Anthony C. Blackburn, San Diego, CA 5,397.793 A 3, 1995 Shaber et al. (US); Yun Shan, San Diego, CA (US); 5,412,119 A 5/1995 Brussee et al. Anna Shifrina, San Diego, CA (US); 5,422,355 A 6/1995 White et al. Scott Stirn, San Diego, CA (US) 5,691.362 A 11/1997 McCormicket al. 5,750,520 A 5/1998 Danilewicz et al. (73) Assignee: Arena Pharmaceuticals, Inc., San 5,856.5035,795,895 A 8,1/1999 1998 AnchAS al. Diego, CA (US) 5,861,393 A 1/1999 Danilewicz et al. 5,908,830 A 6/1999 Smith et al. (*) Notice: Subject to any disclaimer, the term of this 5,925,651 A 7/1999 Hutchinson patent is extended or adjusted under 35 3. A 3: As al U.S.C. 154(b) by 567 days. 5,958,943- 4 A 9/1999 Laufera etca. al. 6,087,346 A 7/2000 Glennon et al. (21) Appl. No.: 13/820,095 6,218,385 B1 4/2001 Adam et al. 6,900,313 B2 5/2005 Wasserscheid et al. (22) PCT Filed: Aug. 31, 2011 6,953,787 B2 * 10/2005 Smith .................
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • Ep 2089382 B1
    (19) TZZ Z¥ _T (11) EP 2 089 382 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 401/14 (2006.01) C07D 413/14 (2006.01) 24.10.2012 Bulletin 2012/43 C07D 471/04 (2006.01) C07D 487/04 (2006.01) C07D 491/048 (2006.01) C07D 491/052 (2006.01) (2006.01) (2006.01) (21) Application number: 07862400.4 C07D 495/04 A61K 31/551 A61P 3/04 (2006.01) A61P 25/20 (2006.01) C07D 403/14 (2006.01) (22) Date of filing: 30.11.2007 (86) International application number: PCT/US2007/024690 (87) International publication number: WO 2008/069997 (12.06.2008 Gazette 2008/24) (54) SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS SUBSTITUIERTE DIAZEPANVERBINDUNGEN ALS OREXIN-REZEPTOR-ANTAGONISTEN ANTAGONISTES DES RÉCEPTEURS DE L’OREXINE SOUS FORME DE COMPOSÉS DE DIAZÉPANE SUBSTITUÉS (84) Designated Contracting States: • COX, Christopher D. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Rahway, NJ 07065-0907 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • MERCER, Swati P. SI SK TR Rahway, NJ 07065-0907 (US) Designated Extension States: • ROECKER, Anthony J. HR RS Rahway, NJ 07065-0907 (US) (30) Priority: 01.12.2006 US 872393 P (74) Representative: Buchan, Gavin MacNicol 16.07.2007 US 959742 P Merck Sharp & Dohme Limited European Patent Department (43) Date of publication of application: Hertford Road 19.08.2009 Bulletin 2009/34 Hoddesdon Hertfordshire EN11 9BU (GB) (60) Divisional application: 11177692.8 / 2 392 572 (56) References cited: EP-A- 0 794 178 WO-A-03/041711 (73) Proprietor: Merck Sharp & Dohme Corp.
    [Show full text]
  • List of Withdrawn Drugs
    List of withdrawn drugs WRITEN BY LAIMA JONUSIENE To prove that the drug companies make mistakes with our lives we publish this list. Drugs are rushed onto the market for profit. The testing of the drugs is on the major indication. Side effects are NOT tested pre and post. Side effects are observed NOT tested. The expense of pre and post side effect testing is astounding. So it is not done. Side effects are then seen in the public use and a drug is removed from the market after killing or hurting people. There is a special law that prohibits you from suing a drug company for damages unless you can prove they knew it was harmful and sold it anyway. This means there is even less need to test side effects and or report them during the testing process. https://www.youtube.com/watch?v=h7Sd0uBc6eE - How a drug pill is brought to the market. Some drugs have been withdrawn from the market because of risks to the patients. Usually this has been prompted by unexpected adverse effects that were not detected during Phase III clinical trials and were only apparent from postmarketing surveillance data from the wider patient community. This list is not limited to drugs that were ever approved by the FDA. Some of them (Lumiracoxib, Rimonabant, Tolrestat, Ximelagatran and Zimelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the U.S., when side effects became clear and their developers pulled them from the market. Likewise LSD was never approved for marketing in the U.S.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Predicting the Function of Drug-Like Molecules Methods and Applications
    Predicting the function of drug-like molecules methods and applications Inaugural-Dissertation to obtain the academic degree Doctor rerum naturalium (Dr. rer. nat.) submitted to the Department of Biology, Chemistry and Pharmacy of Freie Universität Berlin by Hao Wang from Liupanshui, Guizhou province, People’s Republic of China January 2017 Diese Arbeit wurde in dem Zeitraum von November 2012 bis Januar 2017 unter der Leitung von Prof. Dr. Ernst Walter Knapp am Institute für Chemie und Biochemie der Freien Universität Berlin im Fachbereich Biologie, Chemie und Pharmazie durchgeführt. 1. Gutacher: Prof. Dr. Ernst-Walter Knapp 2. Gutacher: Prof. Dr. Gerhard Wolber Disputation am ___16. 3. 2017_________ Statutory Declaration I hereby testify that this thesis is the result of my own work and research, except for any explicitly referenced material, whose source is listed in the bibliography. This work contains material that is the copyright property of others, which must not be reproduced without the permission of the copyright own. Acknowledgement First of all, I would like to thank Prof. Dr. Ernst Walter Knapp, China Scholarship Council, Free University of Berlin and Xiamen University for giving me this precious opportunity to study in Germany. I very much appreciate the supervision of Prof. Dr. Ernst Walter Knapp and valuable discussions during my doctoral work. In addition, I would also like to thank Dr. Bentzien Jörg and Dr. Ingo Mugge in Boehringer-Ingelheim group for their cooperation and valuable suggestions for my research projects. I am thankful for the support and great help of my colleagues in AG Knapp during my doctoral studies.
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • Computational Identification of a Phospholipidosis Toxicophore Using
    Bioorganic & Medicinal Chemistry 22 (2014) 6706–6714 Contents lists available at ScienceDirect Bioorganic & Medicinal Chemistry journal homepage: www.elsevier.com/locate/bmc Computational identification of a phospholipidosis toxicophore using 13C and 15N NMR-distance based fingerprints q Svetoslav H. Slavov a, Jon G. Wilkes a, Dan A. Buzatu a, Naomi L. Kruhlak b, James M. Willard b, ⇑ Joseph P. Hanig b, Richard D. Beger a, a Division of Systems Biology, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Rd., Jefferson, AR 72079, USA b Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA article info abstract Article history: Modified 3D-SDAR fingerprints combining 13C and 15N NMR chemical shifts augmented with inter-atomic Received 25 June 2014 distances were used to model the potential of chemicals to induce phospholipidosis (PLD). A curated Revised 13 August 2014 dataset of 328 compounds (some of which were cationic amphiphilic drugs) was used to generate Accepted 18 August 2014 3D-QSDAR models based on tessellations of the 3D-SDAR space with grids of different density. Composite Available online 27 August 2014 PLS models averaging the aggregated predictions from 100 fully randomized individual models were gen- erated. On each of the 100 runs, the activities of an external blind test set comprised of 294 proprietary Keywords: chemicals were predicted and averaged to provide composite estimates of their PLD-inducing potentials Phospholipidosis (PLD+ if PLD is observed, otherwise PLD ). The best performing 3D-QSDAR model utilized a grid with a Toxicophore À Fingerprint density of 8 ppm  8 ppm in the C–C region, 8 ppm  20 ppm in the C–N region and 20 ppm  20 ppm in Quantitative spectral data–activity the N–N region.
    [Show full text]
  • Doping Im Sport W.Schänzer Institut Für Biochemie Der Deutschen Sporthochschule Köln
    Skript 8.9.2001 Doping im Sport W.Schänzer Institut für Biochemie der Deutschen Sporthochschule Köln Inhalt Seite Einleitung 2 Doping-Definition 2 Stimulantien 5 Amphetamin 6 Coffein 8 Ecstasy 9 Bromantan 10 Narkotika 12 Morphin 12 Anabole Wirkstoffe 15 Anabolika (anabol androgene Steroidhormone) 15 Wirkungen des Testosterons 17 Nebenwirkungen von Anabolika 19 Endokrines System 21 ß2-Agonisten 24 Diuretika 26 Peptidhormone und Analoge 27 HCG ('Schwangerschaftshormon') 28 EPO (Erythropoietin) 29 HGH (Wachstumshormon) 31 Verbotene Methoden 33 Blutdoping 33 Manipulationen (pharmakol., chem., phys.) 35 Plasmaexpander und künstliche Sauerstoffträger 35 Eingeschränkt zugelassene Wirkstoffe 37 Cannabis 37 Lokalanästhetika 39 Corticosteroide 40 Beta-Blocker 42 Kreatin - Doping oder Substitution? 43 Ausführliche Dopinglisten 44 Literatur 48 2 Doping im Sport 1 Einleitung Die Verbesserung der körperlichen Leistungsfähigkeit unter Zuhilfenahme von pharmakologischen Wirkstoffen ist sicherlich ein alter Wunschtraum der Menschheit. Hierbei sind wirksame Substanzen, die aus pflanzlichen Naturstoffen isoliert bzw. zu medizinischen Zwecken synthetisiert wurden, um entsprechende Krankheitszustände zu heilen, immer wieder verwendet worden. Bereits in der Antike wurden bei Sportwettkämpfen stimulierende Substanzen eingesetzt, um Vorteile im Wettkampf zu erzielen. Inwieweit in der ersten Hälfte des 20. Jahrhunderts mit Wiederbeginn der Olympischen Spiele bis Ende der 60er Jahre Dopingsubstanzen zur Leistungssteigerung im Sport eingesetzt wurden, kann nur vermutet werden. Auf jeden Fall gab es noch keine Regeln, die Doping einschränkten bzw. verboten. Nachdem es in den 60er Jahren zu einigen Todesfällen im Radrennsport, insbesondere in Verbindung mit der Einnahme von Stimulanzien aus der Reihe der Amphetamine, gekommen war, wurden von den Sportverbänden Anti-Doping- Regeln aufgestellt. Bekannte Todesfälle waren z.B. die des Radfahrers Tom Simpson, der 1967 während der Tour de France tödlich zusammenbrach.
    [Show full text]